glioblastomas
Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Transglutaminase 2 inhibitor, KCC009, disrupts <span class="gene" id="17099729-0-47-58">fibronectin</span> assembly in the extracellular matrix and sensitizes orthotopic <span class="disease" id="17099729-0-122-135">glioblastomas</span> to chemotherapy.